Reiji Fukano

10PUBLICATIONS
34CO-AUTHORS
Oncology and carcinogenesis not elsewhere classifiedInfant and child healthNanotoxicology, health and safetyHaematological tumoursNeonatology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Dec 29, 2025
Phase 1/2 Study of Crizotinib in Children With Relapsed/Refractory ALK-Positive Anaplastic Large Cell Lymphoma or Neuroblastoma in Japan.

Tetsuya Mori, Akiko Kada, Tomoo Osumi

|Dec 19, 2023
Rituximab with standard LMB chemotherapy in pediatric high-risk mature B-cell non-Hodgkin lymphoma: A report from the JPLSG B-NHL14 trial.

Tetsuya Mori, Tomoo Osumi, Akiko Kada

|Jul 29, 2022
Low NUDT15 expression levels due to biallelic NUDT15 variants and 6-mercaptopurine intolerance.

Masanori Yoshida, Scott A Brown, Takaya Moriyama

|Jan 06, 2022
G3BP2-KIT drives leukemia amenable to kinase inhibition in Ph-like ALL.

Ilaria Iacobucci, Reiji Fukano, Jake D Friske

|Jul 14, 2021
Characteristics of genetic alterations of peripheral T-cell lymphoma in childhood including identification of novel fusion genes: the Japan Children's Cancer Group (JCCG).

Kentaro Ohki, Nobutaka Kiyokawa, Satoru Watanabe

|Oct 03, 2020
Alectinib for relapsed or refractory anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: An open-label phase II trial.

Reiji Fukano, Tetsuya Mori, Masahiro Sekimizu

Pageof 2

Frequent Collaborators

3 joint publications

Tomoo Osumi

3 joint publications

Ryoji Kobayashi

2 joint publications

Tetsuo Mitsui

2 joint publications

Naoto Fujita